logo-loader

Futura Medical announces ‘highly encouraging results’ for its erectile dysfunction gel

Last updated: 15:19 25 Apr 2018 BST, First published: 08:19 25 Apr 2018 BST

laboratory
The company said it is reviewing the implications of the detailed study data with regard to the planning of the Phase III studies

Futura Medical PLC (LON:FUM) shares jumped 16% on Wednesday after the firm revealed positive data from a pharmacokinetic study of MED2002, its topical gel for erectile dysfunction (ED), which contains glyceryl trinitrate (GTN) as its active ingredient.

The AIM-listed firm said the results confirm that increasing the GTN dose beyond 0.2% will result in broadly dose-related higher concentrations in the bloodstream, which supports the company’s strong belief that the higher dose forms of MED2002 should improve efficacy, particularly in the more severe cases of ED.

READ: Futura Medical encouraged by interim data

Futura Medical said GTN demonstrated a rapid rate of absorption and was first detected in blood plasma in four to five minutes, reaching peak levels in the bloodstream within 10 to 12 minutes for all doses.

The company said in a statement that it is reviewing the implications of the detailed study data with regard to the planning of the Phase III studies for MED2002, and expects to make a further announcement on this shortly.

James Barder, chief executive of Futura Medical, said: “The results show the effectiveness of our DermaSys transdermal technology and demonstrate the potential of MED2002 as a rapid and safe treatment option for erectile dysfunction.”

He added: “We look forward to taking these excellent, supportive results into our future clinical programme.”

In early morning trading, Futura shares were up 16.2% to 37.75p.

Futura Medical marks pivotal year with first meaningful revenue from Eroxon...

Futura Medical PLC (AIM:FUM, OTC:FAMDF) CEO James Barder tells Proactive's Stephen Gunnion that 2023 was a pivotal year for the company as it rolled out its innovative sexual health product, Eroxon, designed to treat erectile dysfunction. The over-the-counter availability of Eroxon distinguishes...

on 7/2/24